To include your compound in the COVID-19 Resource Center, submit it here.

Octagam 10% human IV immunoglobulin regulatory update

The European Commission lifted a marketing suspension of Octapharma's Octagam 5% and 10% human IV

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE